Lexicon Pharmaceuticals Announces Exclusive License Agreement with Novo Nordisk for LX9851


Lexicon eligible to receive up to $1 billion in upfront and development, regulatory and sales milestone payments, including $75 million in upfront and near-term milestone payments Lexicon eligible to receive up to $1 billion in upfront and development, regulatory and sales milestone payments, including $75 million in upfront and near-term milestone payments

See the original post here:
Lexicon Pharmaceuticals Announces Exclusive License Agreement with Novo Nordisk for LX9851

Related Posts